Evidence map›Paper›PMID 21138522›Full record

ArticleJournal of thrombosis and haemostasis : JTH2010

Transgenic, inducible RNAi in megakaryocytes and platelets in mice.

M Takiguchi, C James, E C Josefsson, C L Carmichael, P K Premsrirut, S W Lowe, J R Hamilton, D C S Huang, B T Kile, R A Dickins

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Can PRP effectively treat injured tendons?Muscles, ligaments and tendons journal · 2014
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

M TakiguchiMolecular Medicine Division Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Vic., Australia.
C James
E C Josefsson
C L Carmichael
P K Premsrirut
S W Lowe
J R Hamilton
D C S Huang
B T Kile
R A Dickins
The University of Melbourne · AUAustralian Centre for HIV and Hepatitis Virology Research · AUCold Spring Harbor Laboratory · USHoward Hughes Medical Institute · USWalter and Eliza Hall Institute of Medical Research · AU

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008444 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI FROHMAN, MICHAEL A. · 1992 to 2024
$12.6M
Howard Hughes Medical InstituteNIGMS NIH HHS T32 GM008444
6 · The paper itself

Abstract

backgroundRNA interference (RNAi) is a powerful tool for suppressing gene function. The tetracycline (tet)-regulated expression system has recently been adapted to allow inducible RNAi in mice, however its efficiency in a particular cell type in vivo depends on a transgenic tet transactivator expression pattern and is often highly variable.

objectiveWe aimed to establish a transgenic strategy that allows efficient and inducible gene knockdown in particular hematopoietic lineages in mice. METHODS AND

resultsUsing a tet-regulated reporter gene strategy, we found that transgenic mice expressing the rtTA (tet-on) transactivator under control of the cytomegalovirus (CMV) promoter (CMV-rtTA mice) display inducible reporter gene expression with unusual and near-complete efficiency in megakaryocytes and platelets. To test whether the CMV-rtTA transgene can drive inducible and efficient gene knockdown within this lineage, we generated a novel mouse strain harboring a tet-regulated short hairpin RNA (shRNA) targeting Bcl-x(L) , a pro-survival Bcl-2 family member known to be essential for maintaining platelet survival. Doxycycline treatment of adult mice carrying both transgenes induces shRNA expression, depletes Bcl-x(L) in megakaryocytes and triggers severe thrombocytopenia, whereas doxycycline withdrawal shuts off shRNA expression, normalizes Bcl-x(L) levels and restores platelet numbers. These effects are akin to those observed with drugs that target Bcl-x(L) , clearly demonstrating that this transgenic system allows efficient and inducible inhibition of genes in megakaryocytes and platelets.

conclusionsWe have established a novel transgenic strategy for inducible gene knockdown in megakaryocytes and platelets that will be useful for characterizing genes involved in platelet production and function in adult mice.

Indexed as

RNA InterferenceAnimalsBase SequenceBlood PlateletsBlotting, WesternCells, CulturedCytomegalovirusDNA PrimersFlow CytometryGreen Fluorescent ProteinsMegakaryocytesMiceMice, TransgenicPromoter Regions, GeneticDNA PrimersGreen Fluorescent Proteins

Identifiers

PMID21138522
PMCPMC3285240
OpenAlexW1513868997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.